Thermo Fisher Scientific Inc. announced a strategic collaboration with Lyndra Therapeutics, a clinical-stage biopharmaceutical company, to provide global clinical research and commercial manufacturing services for Lyndra’s long-acting oral therapies. This partnership leverages Thermo Fisher’s Accelerator™ Drug Development services, which offer comprehensive CDMO and CRO solutions.
As part of the collaboration, Thermo Fisher will provide clinical research services for Lyndra’s phase 3 pivotal safety study for oral weekly risperidone (LYN-005), which is planned to begin in the first half of 2025. LYN-005 previously met its primary endpoint in the phase 3 pivotal STARLYNG-1 study, demonstrating efficacy compared to daily Risperdal.
Lyndra also plans to utilize Thermo Fisher’s advanced pharmaceutical manufacturing capabilities in Cincinnati, Ohio, for the commercial production of long-acting oral therapies using Lyndra’s LYNX drug delivery platform. This collaboration is a critical step in bringing innovative long-acting oral medicines to broad markets, ensuring reliable and scalable manufacturing and clinical trial operations.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.